drug discovery outsourcing 2014 2024

©noticeThis material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision-gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur-chase and single copy is for personal use only.

Drug Discovery Outsourcing World Market Forecast 2014-2024 & Future

Prospects for Leading Companies

www.visiongain.com

Contents

1.1 Market Highlights

1.2 Overview of the Report Content

1.3 Research and Analysis Methods

1.4 Glossary of Terms Related to Drug Discovery Outsourcing

2.1 What is Outsourcing?

2.1.1 Drug Discovery Outsourcing: Forming Global Networks

2.2 Why Outsource Drug Discovery?

2.2.1 The Move from Tactical to Strategic Outsourcing

2.2.2 The Advantages of Drug Discovery Outsourcing

2.2.3 Technological Advances Making In-House Drug Development Unsustainable

2.2.4 Emerging Markets Offering Reprieve from the Effects of Cost Pressures and Declining

R&D Budgets

2.2.5 Strategic Partnerships: A Prequel to CRO Acquisition

2.2.6 Outsourcing to Improve Efficiency and Reduce Time-to-Market

2.3 Typically Outsourced Processes in Drug Discovery

2.4 A Paradigm Shift for Drug Development

2.4.1 Collaboration with Academia is Key for Pipeline Replenishment

2.5 Quality of Service is Integral for CRO Growth

2.6 Outsourcing: Reducing the Cost of Innovation

3.1 Drug Discovery Outsourcing: Global Market Overview

3.1.1 The Global Drug Discovery Outsourcing Market in 2012 and 2013

1. Executive Summary

2. An introduction to Drug Discovery Outsourcing

3. Global Drug Discovery Outsourcing Market 2014-2024

www.visiongain.com

Contents

3.2 Global Drug Discovery Outsourcing: Market Forecast 2014-2024

3.2.1 Changing Market Shares by Sector 2014-2024

3.3 Global Chemistry Services Outsourcing Market 2014-2024

3.3.1 The Global Chemistry Services Outsourcing Market in 2012 and 2013

3.3.1.1 Libraries: Important for Cost Reduction and Time Efficiency

3.3.1.2 Custom Synthesis: A Major Driver for Long-Term Strategic Partnerships

3.3.1.3 Building Blocks: Promotes Efficiency of Drug Synthesis

3.3.2 Global Chemistry Services Outsourcing Forecast 2014-2024

3.4 Global Biology Services Outsourcing Market 2014-2024

3.4.1 The Global Biology Services Outsourcing Market in 2012 and 2013

3.4.1.1 Target Identification

3.4.1.2 Target Validation

3.4.2 Global Biology Services Outsourcing Forecast 2014-2024

3.5 Global Lead Optimization Market 2014-2024

3.5.1 The Global Lead Optimization Market in 2012 and 2013

3.5.1.1 ADMET Screening: To Prevent Late Stage Failure of Clinical Trials

3.5.2 Global Lead Optimisation Forecast 2014-2024

3.6 Global Lead Identification and Screening Outsourcing Market 2014-2024

3.6.1 The Global Lead Identification and Screening Outsourcing Market in 2012 and 2013

3.6.1.1 Methodologies of Lead Identification

3.6.2 Global Lead Identification and Screening Outsourcing Market: Forecast 2014-2024

4.1 Drug Discover Outsourcing – A Game of Supply versus Demand

4.1.1 The Global Distribution of Drug Discovery Outsourcing in 2012 and 2013

4.2 Leading National Markets: Forecast 2014-2024

4.2.1 Changing Market Shares by Region 2014-2024

4.3 Regional Drug Discovery Outsourcing Markets: Analysis and Forecasts 2014-2024

4.3.1 United States: Patent Expiries Boosting Pipeline Investment

4. Leading National Markets 2014-2024

www.visiongain.com

Contents

4.3.2 The EU5 Markets

4.3.2.1 EU5: Changing Market Shares by Country 2014-2024

4.3.2.2 Germany: Europe’s Largest Drug Discovery Outsourcing Market

4.3.2.3 UK: A Service-Oriented Market

4.3.2.4 France: Market Dominated by Large CROs

4.3.2.5 Italy: Heavy Investment from Multinational CROs will Drive Growth

4.3.2.6 Spain: An Immature Market with Potential

4.3.3 Japan: An Aging Population Putting a Strain on Pharma

4.3.4 The BRIC Nations: Rapid Growth will Fuel the Global Market

4.3.4.1 China: Rapid Market Expansion Fuelled by Acquisitions

4.3.4.2 India: R&D Infrastructure Needed for Market Boom

4.3.4.3 Brazil: The Largest Pharma Market in Latin America

4.3.4.4 Russia: A Highly Fragmented Market

4.3.5 South Korea: A Pharmaceutical Powerhouse of the Future

5.1 Drug Discovery Outsourcing: An Expanding Marketplace

5.2 What Makes a Successful Contract Research Organisation?

5.2.1 A Business Model that Encourages Cost Reduction

5.2.2 A Workforce with Proven Expertise

5.2.3 Good Working Relationship: A Requisite for Outsourcing

5.2.4 Adequate Intellectual Property Protection

5.2.5 Huge Emphasis is placed on Communication and Timeliness

5.3 Leading Companies in the Drug Discovery Outsourcing Arena

5.4 Albany Molecular Research (AMRI)

5.4.1 SMARTSOURCING for Enhanced Decision-Making

5.4.2 AMRI’s Drug Discovery Services

5.4.3 AMRI’s Licensing Agreements and Drug Discovery Collaborations

5.4.4 AMRI Revenue Forecast 2014-2024

5. Leading Companies Offering Drug Discovery Services

www.visiongain.com

Contents

5.5 Aptuit

5.5.1 INDIGO: Aptuit’s Accelerated Drug Development Programme

5.5.2 Strategic Partnerships Strengthening Aptuit’s Outlook

5.6 Charles River Laboratories

5.6.1 Charles River: Strong Sales of Research Models Boosts Revenue

5.6.2 Charles Rivers: Corporate Restructuring to Maximise Efficiency

5.6.3 Charles River: Revenue Analysis and Forecast 2014-2024

5.7 Covance

5.7.1 Refocusing Early-Stage Efforts

5.7.2 Covance Strategic Partnerships

5.7.3 Covance: Revenue Analysis and Forecast 2014-2024

5.8 Cyprotex: An ADME-Tox Service Provider

5.8.1 Cyprotex: Revenue Analysis and Forecast 2014-2024

5.9 Domainex: Pipeline Products Showing Promise

5.10 Evotec: Discovery Alliances and Development Partnerships

5.10.1 Action Plan 2016 – Leadership in Drug Discovery Solutions

5.10.2 Evotec: Revenue Analysis and Forecast 2014-2024

5.11 Galapagos

5.11.1 Galapagos – Recent Activity

5.12 GenScript: A Biology-Focused Research Company

5.12.1 GenScript: Agreements and Partnerships

5.13 Pharmaceutical Product Development (PPD): A Leading CRO

5.13.1 PPD: Agreements, Strategic Partnerships and Private Merger

5.13.2 PPD’s Expansion in the Asian Markets

5.13.3 PPD and BioDuro: A Key Acquisition for Chinese Market Dominance

5.14 Quintiles: The World’s Largest Biopharmaceutical Services Company

5.14.1 Quintiles: Acquisition of Advion Bioanalytical Labs

5.14.2 Quintiles – New Developments

5.14.3 Quintiles: Revenue Analysis and Forecast 2014-2024

5.15 WIL Research Laboratories

5.16 WuXi AppTec: China’s Leading CRO

www.visiongain.com

Contents

5.16.1 WuXi AppTec: Revenue Analysis, 2008-2012

5.16.2 WuXi’s Strategic Partnerships and Recent Developments

5.16.3 WuXi AppTec: Revenue Forecast 2014-2024

6.1 SWOT Analysis of the Drug Discovery Outsourcing Market 2014-2024

6.2 Strengths

6.2.1 Cost Reduction: A Central Driver for Outsourcing

6.2.2 Efficient Turnaround Times is Key for the Growth of Outsourcing

6.2.3 Acquisitions and Mergers allows for a more Comprehensive Service Provision

6.3 Weaknesses

6.3.1 The Negative Effects of Falling R&D Spending

6.3.2 Market Saturation and Poorly-Defined Service Offerings

6.4 Opportunities

6.4.1 The Available Scope for the Expansion of CROs

6.4.2 Targeted Therapies: Advances in Biologics and Orphan Drugs

6.4.3 Orphan Drug Development: An Opportunity for Higher Premiums

6.4.4 The Rise of Biologics and Biosimilars

6.4.5 The Multi-directional Expansion of CROs

6.4.6 The Rise of Virtual Pharma Companies

6.5 Threats

6.5.1 A Competitive Market Causing Smaller CROs to Miss Out

6.5.2 Private-Public Alliances May Become a Threat to Drug Discovery Outsourcing

6.5.3 Intellectual Property Leaks and the Challenges of Technology Transfer

6.5.4 Resource Sharing by Pharma Companies Could Restrain CRO Growth

6.6 Porter’s Five Force Analysis of the Drug Discovery Outsourcing Market

6.6.1 Power of Suppliers: Medium

6.6.2 Threat of Substitutes: Medium

6.6.3 Rivalry among Competitors: High

6. Drug Discovery Outsourcing Market: Analysis and Trends

www.visiongain.com

Contents

6.6.4 Bargaining Power of Buyers: High

6.6.5 Threat of New Entrants: Medium

7.1 Interview with Dr Barbara Slusher, Professor of Neurology, Psychiatry, and Neuroscience at

Johns Hopkins University and co-Founder and President, Academic Drug Discovery Consortium

7.1.1 Current State of the Drug Discovery Outsourcing Industry

7.1.2 Drug Discovery Collaborations between Pharma and Academia

7.1.3 Academic Research: A Restraint to CRO Growth?

7.1.4 The Changing Outsourcing Model: Implications for Pharma R&D

7.1.5 The Move towards Shared Risk Partnerships

7.1.6 Hot Therapeutic Areas in Drug Discovery

7.1.7 Views on the Future Prospects of the Market

7.2 Interview with Dr Mark Craighead, Director of Scientific Strategy, Redx Pharma

7.2.1 Changes in the Industry’s Pricing Model

7.2.2 Redx Pharma’s Services and Growth Plans

7.2.3 Is Outsourcing Earlier the Key to Solving Pharma’s R&D Problems?

7.2.4 Appealing Therapeutic Areas and the Role of the Asian Markets

8.1 Market Overview

8.2 A Move towards Biology Services

8.3 The Rise of the Asian Outsourcing Industry

8.4 Unmet Therapeutic needs will Stimulate Drug Discovery Drive

8.5 Alliances and Collaborations Will Continue to Dominate the Market

7. Expert Opinions

8. Conclusion

www.visiongain.com

Contents

Table 2.1 Indication of Functions Outsourced in the Different Stages of the Drug R&D Process, 2013

Table 2.2 Selected Drug Discovery Outsourcing Alliances 2012- 2013

Table 2.3 Selected Drug Discovery Outsourcing Alliances 2009- 2012

Table 3.1 PhRMA’s Historical Estimate for its Member’s R&D Spending ($bn)

Table 3.2 The Global Drug Discovery Outsourcing Market: Revenues ($bn), Market Shares (%) and

Growth (%) by Sector, 2012 and 2013

Table 3.3 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,

CAGR%) by Sector, 2012-2017

Table 3.4 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%)

by Sector, 2017-2024

Table 3.5 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2012-2017,

2017-2024, and 2012-2024

Table 3.6 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017,

2024

Table 3.7 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2012, 2017,

2024

Table 3.8 The Chemistry Services Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%),

2012-2024

Table 3.9 The Biology Services Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%),

2012-2024

Table 3.10 The Global Lead Optimisation Outsourcing Market: Revenue Forecast ($bn, AGR%,

CAGR%), 2012-2024

Table 3.11 Selected Drug Discovery Lead Optimisation Partnerships

Table 3.12 Selected Methods for Sourcing Lead Compounds, 2013

Table 3.13 The Global Lead Identification and Screening Market: Revenue Forecast ($bn, AGR%,

CAGR%), 2012-2024

Table 4.1 The Global Drug Discovery Outsourcing Market: Revenues ($bn) and Growth (%) by

Region, 2012 and 2013


List of Tables

www.visiongain.com

Contents

by Region, 2012-2017


by Region, 2017-2024

Table 4.4 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-2017,

2017-2024, and 2012-2024

Table 4.5 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2012,

2017, 2024

Table 4.6 The US Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market

Share (%) and CAGR (%), 2012-2024

Table 4.7 US Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-

2024

Table 4.8 The EU5 Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Market Share

(%) and CAGR (%), 2012-2024

Table 4.9 The EU5 Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%) by

Country, 2012-2017

Table 4.10 The EU5 Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%)

by Country, 2017-2024

Table 4.11 The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Country, 2012-

2017, 2017-2024, and 2012-2024

Table 4.12 The EU5 Drug Discovery Outsourcing Market: Market Shares (%) by Country, 2012,

2017, 2024

Table 4.13 The German Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank,

Market Share (%) and CAGR (%), 2012-2024

Table 4.14 The German Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%,

CAGR%), 2012-2024

Table 4.15 The UK Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market

Share (%) and CAGR (%), 2012-2024

Table 4.16 The UK Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%),

2012-2024

Table 4.17 The French Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank,


www.visiongain.com

Contents

Table 4.18 The French Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%,

CAGR%), 2012-2024

Table 4.19 The Italian Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank,


Table 4.20 The Italian Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%,

CAGR%), 2012-2024

Table 4.21 The Spanish Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank,


Table 4.22 The Spanish Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%,

CAGR%), 2012-2024

Table 4.23 The Japanese Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank,


Table 4.24 The Japanese Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,

CAGR%), 2012-2024

Table 4.25 The Chinese Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank,


Table 4.26 The Chinese Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,

CAGR%), 2012-2024

Table 4.27 The Indian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank,


Table 4.28 The Indian Population: Demographic Forecast by Age Group (%), 2015, 2020, 2025

Table 4.29 The Indian Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,

CAGR%), 2012-2024

Table 4.30 The Brazilian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank,


Table 4.31 The Brazilian Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,

CAGR%), 2012-2024

Table 4.32 The Russian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank,


Table 4.33 The Russian Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,

CAGR%), 2012-2024

www.visiongain.com

Contents

Table 4.34 The South Korean Drug Discovery Outsourcing Market Forecast: Market Size ($bn),

Rank, Market Share (%) and CAGR (%), 2012-2024

Table 4.35 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,

CAGR%), 2012-2024

Table 5.1 Albany Molecular Research (AMRI): Historical Revenue ($m, AGR %), 2008-2012

Table 5.2 AMRI: Services offered and Descriptions, 2013

Table 5.3 AMRI: Drug Discovery and Development Programmes and Project Stage

Table 5.4 Albany Molecular Research (AMRI): DDS Revenue Forecast ($m, AGR %, CAGR%), 2012-

2024

Table 5.5 Aptuit: Services Offered and their Descriptions, 2013

Table 5.6 Charles River Laboratories: Selected Services Provided, 2013

Table 5.7 Charles River: Historical Revenue ($m, AGR %), 2010-2012

Table 5.8 Charles River: Historical Revenue ($m) by Segment, 2009-2012

Table 5.9 Charles River: Revenue Forecast ($m, AGR %, CAGR%), 2012-2024

Table 5.10 Covance: Historical Revenue ($bn) by Business Segment, 2009-2012

Table 5.11 Covance: Early Development Revenue Forecast ($m, AGR %, CAGR%), 2012-2024

Table 5.12 Selected Cyprotex Partnerships, 2013

Table 5.13 Cyprotex: Historical Revenue ($m) by Region, 2010-2012

Table 5.14 Cyprotex: Revenue Forecast ($m, AGR %, CAGR%), 2012-2024

Table 5.15 Domainex’s Collaborations and Partnerships, 2013

Table 5.16 Evotec: Historical Revenue ($m, AGR %), 2008-2012

Table 5.17 Evotec Action Plan 2016: Leadership in Drug Discovery Solutions

Table 5.18 Evotec: Revenue Forecast ($m, AGR %, CAGR%), 2012-2024

Table 5.19 Galapagos Pipeline Projects and Development stages, 2013

Table 5.20 Galapagos: Historical operating Income ($m) by Business Sector, 2011 and 2012

Table 5.21 Genscript: Services Offered and Descriptions, 2013

Table 5.22 Quintiles: Historical Revenue ($bn, AGR %), 2008-2012

Table 5.23 Quintiles: Revenue Forecast ($bn, AGR %, CAGR%), 2012-2024

Table 5.24 WuXi AppTec: Pharmaceutical Laboratory Services and Descriptions, 2013

Table 5.25 WuXi AppTec: Historical Revenue ($m) by Business Segment, 2008-2012

Table 5.26 WuXi AppTec: Laboratory Services Revenue Forecast ($m, AGR %, CAGR%), 2012-2024

www.visiongain.com

Contents

Table 6.1 Drug Discovery Outsourcing: Market Drivers, 2014-2024

Table 6.2 Drug Discovery Outsourcing: Market Restraints, 2014-2024

Table 6.3 SWOT Analysis of the Drug Discovery Outsourcing Industry, 2014-2024

Table 6.4 NIH Biomarker Definitions, 2013

Table 8.1 Projected Global Drug Discovery Outsourcing Market Size ($bn, CAGR%): 2012, 2017,

2020, 2024

Table 8.2 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017,

2020, 2024

Table 8.3 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2012, 2017,

2020, 2024

www.visiongain.com

Contents

Figure 2.1 Selected Tasks being Outsourced in the Pharma Industry, 2013

Figure 2.2 Typical Stages of the Drug Development Cycle

Figure 3.1 PhRMA’s Historical Estimate for its Member’s R&D Spending ($bn)

Figure 3.2 The Global Drug Discovery Outsourcing Market: Revenues ($bn) by Sector, 2012 and

2013

Figure 3.3 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2017

Figure 3.4 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2017-2024

Figure 3.5 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2012-2017



Figure 3.8 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017,

2024

Figure 3.9 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Sector, 2012



Figure 3.12 The Chemistry Services Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 3.13 The Biology Services Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 3.14 An Overview of ADMET Screening in Drug Discovery

Figure 3.15 The Global Lead Optimisation Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 3.16 Typical Steps in the Lead Screening Process

Figure 3.17 The Global Lead Identification and Screening Market: Revenue Forecast ($bn), 2012-

2024

Figure 4.1 The Global Drug Discovery Outsourcing Market: Revenues ($bn) by Region, 2012

Figure 4.2 US, EU5, and Japan Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-

2024

Figure 4.3 China, India, South Korea, Brazil, and Russia Drug Discovery Outsourcing Market:

Revenue Forecast ($bn), 2012-2024

Figure 4.4 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-2017


List of Figures

www.visiongain.com

Contents


Figure 4.7 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2012



Figure 4.10 US Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 4.11 Germany, UK, France, Italy, and Spain Drug Discovery Outsourcing Market: Revenue

Forecast ($m), 2012-2024

Figure 4.12 The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-

2024

Figure 4.13 The EU5 Drug Discovery Outsourcing Market: Market Shares (%) by Country, 2012

Figure 4.14 The German Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024

Figure 4.15 The UK Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024

Figure 4.16 The French Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024

Figure 4.17 The Italian Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024

Figure 4.18 The Spanish Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024

Figure 4.19 Japanese Over-65 Population and Forecast (%): 2010, 2013, 2035, 2060

Figure 4.20 The Japanese Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 4.21 Chinese Demographics: Over 65 Population and Forecast (millions), 1950, 2010, 2050

Figure 4.22 The Chinese Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 4.23 The Indian Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 4.24 The Brazilian Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 4.25 The Russian Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 4.26 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-

2024

Figure 5.1 Albany Molecular Research (AMRI): Historical Revenue ($m), 2008-2012

Figure 5.2 Albany Molecular Research (AMRI): Revenue Forecast ($m), 2012-2024

Figure 5.3 Charles River: Historical Revenue ($m), 2010-2012

Figure 5.4 Charles River: Historical Revenue ($m) by Segment, 2012

Figure 5.5 Charles River: Revenue Forecast ($m), 2012-2024

Figure 5.6 Covance: Historic Revenue ($bn), 2009-2012

Figure 5.7 Covance: Revenue ($bn) by Segment, 2012

www.visiongain.com

Contents

Figure 5.8 Covance: Early Development Revenue Forecast ($m), 2012-2024

Figure 5.9 Cyprotex: Historical Revenue ($m), 2010-2012

Figure 5.10 Cyprotex: Revenue Shares (%) by Region, 2012

Figure 5.11 Cyprotex: Revenue Forecast ($m), 2012-2024

Figure 5.12 Evotec: Historical Revenue ($m), 2008-2012

Figure 5.13 Evotec: Revenue Forecast ($m), 2012-2024

Figure 5.14 Galapagos: Revenue Share (%) by Business Sector, 2012

Figure 5.15 Quintiles: Historical Revenue ($bn), 2008-2012

Figure 5.16 Quintiles: Revenue Forecast ($bn), 2012-2024

Figure 5.17 WuXi AppTec: Historical Revenue ($m) by Business Segment, 2008-2012

Figure 5.18 WuXi AppTec: Laboratory Services Revenue Forecast ($m), 2012-2024

Figure 6.1 Porter’s Five Force Analysis of the Drug Discovery Outsourcing Market, 2013

Figure 8.1 Projected Global Drug Discovery Outsourcing Market Size ($bn): 2012, 2017, 2020, 2024

Figure 8.2 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017,

2020, 2024

Figure 8.3 Global Over-60 Population Forecast (%): 1950, 2009, 2050

Figure 8.4 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2012,

2017, 2020, 2024

www.visiongain.com

Contents

Abbott

Accugenix

Advion Bioanalytical

Albany Molecular Research Inc (AMRI)

Andromeda Biotech (Teva)

Apredica (Cyprotex)

Aptuit

Argenta (Galapagos)

AstraZeneca

Bayer

Behrman Capital

BioCity

BioDuro (PPD)

BioFocus (Galapagos)

Biopontis Alliance

Boehringer Ingelheim

Bristol-Myers Squibb

Caprion Proteomics

Carlyle Group

Catalent Pharma Solutions

Cerebricon (Charles River)

Charles River Laboratories

ChemBridge

ChemDiv

Compound Focus (Evotec)

Covance

Crucell

Cyprotex

Companies Mentioned in this Report

www.visiongain.com

Contents

Discovery Partners International

Domainex

Dow AgroSciences

Dow Chemical Company

Elan

Eli Lilly

Evotec

Fidelity Growth Partners India (FGPI)

Fidelta (Galapagos)

Furiex Pharmaceuticals

Galapagos

Genentech

GenScript

GlaxoSmithKline (GSK)

Glycoform

Great Lakes Chemical Corporation

Hangzhou Tigermed Consulting

Hellman & Friedman

Hypha Discovery

i3 Research (inVentiv Health)

ICON

Inpharmatica

InSphero

InVentiv Health

Johnson & Johnson (J&J)

Janssen Pharmaceutical Group

Kinaxo

Knopp Biosciences

ICON

Immatics

JOINN Laboratories

www.visiongain.com

Contents

Laurus Labs

Lonza

MAB Discovery

MedImmune

Merck & Co.

Microsoft

Midwest BioResearch (WIL Research)

Millipore

Novartis

Ono Pharmaceutical

Oxford Asymmetry International

Parexel

Peking Union Lawke Biomedical Development Limited (PUL)

Pfizer

Myriad RBM

Pharmaceutical Product Development (PPD)

Pharmidex

PharmaNet Development Group (inVentiv Health)

Pharminox

Piedmont Research Center (Charles River)

PRA International

ProSkelia

ProStrakan

Proteome Sciences

Proteros Biostructures GmbH (Proteros)

ProtonMedia

Quintiles

Ricerca Biosciences (WIL Research)

Roche

Samsung

Sanofi

www.visiongain.com

Contents

Sareum Holdings Plc

Servier

ShangPharma Corporation

Shionogi

Sirius Analytical

Solvo Biotechnology

Swiss Pharma Contract

Sygnature Discovery

SYNthesis Med Chem

Taijitu Biologics

Takeda

Teva

The Dow Chemical Company

Tibotec

TRAC Microbiology

TransGenic

UCB

VitualScopics

WIL Research Laboratories

WuXi AppTec

WuXi PharmaTech

www.visiongain.com

Contents

American Cancer Society

Associação Brasileira de CROs (Abracro)

Beijing Genomics Institute

Bundesverband Medizinischer Auftragsinstitute (BVMA)

CHDI Foundation

Dundee University

Food and Drug Administration (US FDA)

Indiana Clinical and Translational Sciences Institute (CTSI)

Johns Hopkins University

Massachusetts General Hospital

National Institute for Population and Social Security Research (IPSS)

National Institutes of Health (NIH)

Pharmaceutical Research and Manufacturers of America (PhRMA)

Russian Corporation of Nanotechnologies

Southwestern Medical Center

The European Innovative Medicine Initiative (IMI)

The European CRO Federation (EUCROF)

The Institute of Cancer Research

The Organization for Economic Cooperation and Development (OECD)

University of Manchester

University of North Carolina

Wellcome Trust

World Health Information Science Consultants (WHISCON)

World Health Organization (WHO)

World Trade Organization (WTO)

Organisations Mentioned in this Report

www.visiongain.com

Drug Discovery Outsourcing: World Market Forecast 2014-2024 & Future Prospects for Leading Companies

Figure 2.1 Selected Tasks being Outsourced in the Pharma Industry, 2013

2.2 Why Outsource Drug Discovery? The global recession of 2008, triggered by the US housing bubble, has added to the global

pharmaceutical industry’s existing challenges of declining pipeline products. The industry is

currently experiencing one of the most challenging periods in its history, in terms of the level of

capital available to be used. The cost of taking a drug to the market has risen rapidly over the past

three decades. Development costs for a drug is now estimated to be anywhere between $800m

and $1bn. The pharmaceutical industry has invested a large amount of money into R&D over the

past few decades but the number of novel drug entities reaching the clinic has declined. All of

Pre-Clinical and Clinical

Trials

Animal models

Clinical trial manageme

nt

Manufacturing and

packaging

Clinical trial data

managemet

Drug Discovery

and Developme

nt

Target identification

Assay developme

nt and ADMET

High throughput screening

Lead Optimisation

Registration and

Marketing

Drug manufacture

Lifecycle manageme

nt

Regulatory affairs

Sales and marketing

Source: Visiongain 2013

www.visiongain.com


Table 4.35 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast

($bn, AGR%, CAGR%), 2012-2024

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024South Korean Market ($bn) 0.2 0.2 0.2 0.3 0.3 0.4 0.5 0.6 0.6 0.7 0.8 0.9 1.0Annual Growth (%) 18 20 22 22 21 18 15 15 14 13 14 12CAGR (% 2012-2017 & 2017-2024) 20.6 14.4CAGR (% 2012-2024) 16.9

Figure 4.26 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast

($bn), 2012-2024

Visiongain believes that the tax breaks afforded to local drug makers that invest in research and

development, in particular, the subsidies afforded to those involved in joint drug-development

0.2 0.2 0.3

0.3 0.4

0.5 0.6

0.6 0.7

0.8

0.9

1.0

0.0

0.2

0.4

0.6

0.8

1.0

1.2

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

Rev

enue

($bn

)

Year



www.visiongain.com


Table 5.3 AMRI: Drug Discovery and Development Programmes and Project Stage

Disease Area/Target Lead Discovery Lead Optimisation

Pre-clinical Development

Phase I Clinical

Phase II Clinical

Antibacterials InfectionGLY-T Schizophrenia5-HT6 CognitionMCH-1 ObesityBiogenic Amines Central Nervous System5-HT3 Irritable Bowel SyndromeTubulin Inhibitor Oncology

5.4.4 AMRI Revenue Forecast 2014-2024 Visiongain predicts sustained growth for AMRI’s future revenue. Increasing demand for chemistry

services, especially from the US market will help AMRI grow contract revenue from its DDS

business segment (Discovery, Drug development and Small scale manufacturing). This will reach

$123.6m in 2017 (Figure 5.2). This represents a CAGR of 11.0% from 2012 to 2017 (Table 5.4).

Table 5.4 Albany Molecular Research (AMRI): DDS Revenue Forecast ($m, AGR %,

CAGR%), 2012-2024

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024AMRI's DDS Revenue ($m) 73.5 83.7 94.6 106.0 114.5 123.6 131.0 138.9 148.6 156.1 162.3 168.8 173.9

Annual Growth Rate (%) 14 13 12 8 8 6 6 7 5 4 4 3CAGR (% 2012-2017 & 2017-2024) 11.0 5.0

CAGR (% 2012-2024) 7.4

Source: AMRI 2013, Visiongain 2013


drug discovery outsourcing 2014 2024

Business

screening outsourcing

drug discover outsourcing

global market overview

strategic outsourcing

drug discovery collaborations

drug discovery outsourcing2

market highlights

market boom